Let's agree the science is good. Let's agree our SAB is outstanding. Let's agree the data so far is good.
What's left to blame for our stagnant and declining PPS? The necessity of a RS. The lack of visible BP interest (We're in talks holds no water after 6 years.) The lack of licensing partners. The need to continually dilute. What happened to 3 of our 5 collaborations? Merck and Affitech the only two left. http://www.peregrineinc.com/index.php?option=com_content&task=view&id=17&Itemid=31
There aren't many things left to point the finger at. Anyone else think management could shoulder some of the blame?
$3.18 down $0.09. will it hold? King must have really impressed them yesterday.
Insanity: doing the same thing over and over again and expecting different results.
Market Data 
Markets 
AI
